Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
AVXLthis companyAnavex Life Sciences Corp.	$1.22	-16.48×	8×	0×	-14.16×	2.3%	0.0%	0.0%	0.0%	-48.9%	-54.2%	-5.1%	0×	2.21×	0×	11.6×	0.0%	1	4.27	2	C
ABSIAbsci Corporation	$11.05	-4.15×	2.52×	170.48×	-4.48×	-99.6%	-319.4%	-4454.2%	-4113.7%	-60.8%	-63.6%	-19.7%	0.03×	0.14×	-596.74×	6.57×	0.0%	4	39.57	1	C-
ARVNArvinas, Inc.	$6.52	-9.27×	1.77×	2.93×	-8.44×	-1590.9%	98.0%	-43.8%	-30.8%	-18.6%	-19.9%	-35.8%	0.02×	1.78×	0×	4.92×	0.0%	3	0.86	3	B-
CTMXCytomX Therapeutics, Inc.	$2.08	-28.4×	5.93×	7.71×	-36.76×	-283.4%	100.0%	-29.3%	-22.8%	-17.5%	-20.5%	-12.9%	0.04×	0.53×	0×	3.09×	0.0%	1	1.34	2	C
ERASErasca, Inc.	$15.30	-8.45×	3.24×	0×	-8.47×	-99.3%	0.0%	0.0%	0.0%	-38.3%	-35.3%	-9.1%	0.14×	0.22×	0×	10.04×	0.0%	1	35.36	1	C-
MBXMBX Biosciences, Inc. Common Stock	$53.81	-13.25×	3.12×	0×	-12.42×	-96.3%	0.0%	0.0%	0.0%	-23.6%	-26.5%	-7.1%	0×	0.86×	0×	24.62×	0.0%	1	58.99	2	C
Peer median	—	-9.27×	3.12×	2.93×	-8.47×	-99.6%	0.0%	-29.3%	-22.8%	-23.6%	-26.5%	-12.9%	0.03×	0.53×	0×	6.57×	0.0%	1	35.36	2	—